Korea Provides Tamiflu Government Stockpile To Roche
This article was originally published in PharmAsia News
To help cope with the rising number of patients with A/H1N1, Korea handed over some of its government stockpile of Tamiflu supplies to Roche.
You may also be interested in...
Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products
SEOUL - South Korea's Green Cross has obtained approval from South Korea's FDA to sell the injectable antiviral drug Rapiacta (peramivir), developed by BioCryst Pharmaceuticals in the U.S., during a government drive to make more flu-fighting medicines available beyond Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)
Roche, GSK Face Compulsory Licensing Of Antivirals If Swine Flu Emergency Hits - South Korean Health Minister
SEOUL - Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) could be manufactured under compulsory licensing in South Korea if the country faces an emergency swine flu threat in the coming months, Health, Welfare and Family Affairs Minister Jeon Jae-Hee said
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.